- Home
- VRCA vs KLRS Comparison
VRCA vs KLRS Comparison
Compare VRCA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- KLRS
- Stock Information
- Founded
- VRCA 2013
- KLRS 2019
- Country
- VRCA United States
- KLRS United States
- Employees
- VRCA N/A
- KLRS N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRCA Health Care
- KLRS Health Care
- Exchange
- VRCA Nasdaq
- KLRS Nasdaq
- Market Cap
- VRCA 58.7M
- KLRS 46.0M
- IPO Year
- VRCA 2018
- KLRS N/A
- Fundamental
- Price
- VRCA $4.41
- KLRS $4.44
- Analyst Decision
- VRCA Hold
- KLRS Strong Buy
- Analyst Count
- VRCA 5
- KLRS 2
- Target Price
- VRCA $60.00
- KLRS $23.00
- AVG Volume (30 Days)
- VRCA 43.5K
- KLRS 726.0K
- Earning Date
- VRCA 11-03-2025
- KLRS 11-15-2025
- Dividend Yield
- VRCA N/A
- KLRS N/A
- EPS Growth
- VRCA N/A
- KLRS N/A
- EPS
- VRCA N/A
- KLRS N/A
- Revenue
- VRCA $14,704,000.00
- KLRS N/A
- Revenue This Year
- VRCA $332.45
- KLRS N/A
- Revenue Next Year
- VRCA $12.85
- KLRS N/A
- P/E Ratio
- VRCA N/A
- KLRS N/A
- Revenue Growth
- VRCA 5.72
- KLRS N/A
- 52 Week Low
- VRCA $3.82
- KLRS $2.14
- 52 Week High
- VRCA $20.01
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- VRCA 29.87
- KLRS 59.74
- Support Level
- VRCA $4.35
- KLRS $3.49
- Resistance Level
- VRCA $5.23
- KLRS $4.90
- Average True Range (ATR)
- VRCA 0.35
- KLRS 0.81
- MACD
- VRCA -0.05
- KLRS 0.01
- Stochastic Oscillator
- VRCA 4.29
- KLRS 32.54
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.